A panel of experts advising the U.S. Food and Drug Administration (FDA) is taking another look at the safety warnings tied to hormone replacement therapy (HRT) for menopause. The therapy, which helps ease symptoms like hot flashes, has been controversial for years due to links to increased risks of breast cancer and heart disease. Now, new research and evolving medical perspectives might lead to updated guidelines—potentially refining who should use HRT and for how long.

The FDA is taking another look at the warnings slapped on hormone therapy for menopause—warnings that, over the years, have scared many women away from a treatment that might actually ease their symptoms. The panel isn’t saying the warnings were wrong, but they’re questioning whether the risks were oversold, leaving some women to tough it out unnecessarily.